Dable Habib J 4

What Happened
Dable Habib, a director of Relay Therapeutics (RLAY), was granted a derivative award covering 32,947 shares on June 9, 2026. The filing reports the grant as an award/acquisition with $0 cash paid at grant. This is a stock-based compensation award (an option) issued to a director—not a market purchase or sale.

Key Details

• Transaction date: 2026-06-09; Form 4 filed: 2026-06-10 (timely — Form 4 due within two business days).
• Reported consideration: $0.00 at grant (award/derivative).
• Amount: 32,947 shares (derivative instrument representing potential common shares).
• Shares owned after transaction: not specified in the filing.
• Footnote: The option vests in full on the earlier of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the grant.
• Transaction code: A (award/grant).

Context
This was a standard equity award to a director as part of compensation; it is a grant of a derivative security (an option) rather than an exercise or sale, so no shares were sold or cashed out at grant. The award will vest according to the stated schedule before the director can convert it to owned shares (and any exercise or sale would be reported separately). Such grants are routine for board members and do not by themselves indicate insider buying or selling sentiment.